IDiyas

For the Inventor, By the Inventor

Baltimore, MD, United States of America

Keith M Maclin

USPTO Granted Patents = 27

Average Co-Inventor Count = 3.9

ph-index = 18

Forward Citations = 899(Granted Patents)


Company Filing History:

goldMedal27 out of 98 
 
Guilford Pharmaceuticals, Inc.
 patents

Years Active: 1998-2003

Loading Chart...
27 patents (USPTO):Explore Patents
1. 6635642 - PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same (2003-10-21),
2. 6514983 - Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage (2003-02-04),
3. 6479471 - NAALADase inhibitors (2002-11-12),
4. 6458775 - NAALADase inhibitors useful as pharmaceutical compounds and compositions (2002-10-01),
5. 6426415 - Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity (2002-07-30),
6. 6413948 - Pharmaceutical compositions and methods of effecting a neuronal activity in an animal using naaladase inhibitors (2002-07-02),
7. 6380211 - Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity (2002-04-30),
8. 6372726 - Methods of cancer treatment using NAALADase inhibitors (2002-04-16),
9. 6346536 - Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same (2002-02-12),
10. 6306889 - Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage (2001-10-23),
11. 6288046 - Phosphonic acid derivatives (2001-09-11),
12. 6271245 - Hydroxamic acid derivatives (2001-08-07),
13. 6265609 - Thio-substituted pentanedioic acid derivatives (2001-07-24),
14. 6197785 - Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity (2001-03-06),
15. 6121278 - Di-n-heterocyclic compounds, methods, and compositions for inhibiting (2000-09-19),

Title: **Keith M Maclin: A Notable Innovator in Pharmaceutical Sciences**

Introduction

Keith M Maclin is a distinguished inventor based in Baltimore, MD, who has made significant contributions to pharmaceutical sciences through his extensive body of work. With an impressive portfolio of 27 patents, he has focused on developing innovative solutions for treating various neurological and cardiovascular conditions. His advancements in the field have paved the way for new therapeutic approaches and improved patient outcomes.

Latest Patents

Among his latest patents, Keith M Maclin's work on PARP inhibitors exemplifies groundbreaking pharmaceutical innovation. The patented methods and compositions aim to address tissue damage resulting from cell damage or death due to necrosis and apoptosis. His inventions focus on treating neural tissue damage arising from ischemia and reperfusion injury, as well as neurological disorders and neurodegenerative diseases. Further applications include the prevention and treatment of vascular stroke, cardiovascular disorders, and other conditions like age-related macular degeneration, cancer, diabetes, and chronic pain. His pharmaceutical compositions also aim to extend the lifespan of cells and alter the gene expression of senescent cells.

Career Highlights

Throughout his career, Keith has collaborated with prominent companies in the pharmaceutical industry, including Guilford Pharmaceuticals, Inc. and Guilford Pharmaceutical Inc. His innovative work has positioned him as a key figure in pharmaceutical research, with contributions that address critical medical needs.

Collaborations

Collaboration has been a vital aspect of Keith’s career. He has worked alongside notable colleagues such as Paul F Jackson and Barbara S Slusher. Together, they have contributed their expertise towards developing therapeutic solutions that address complex medical challenges.

Conclusion

Keith M Maclin's invention journey reflects his dedication to enhancing healthcare through innovative pharmaceutical solutions. His extensive patent portfolio signifies his commitment to improving the lives of individuals affected by various diseases and disorders, ensuring his legacy as a pioneering inventor in the field of pharmaceutical sciences.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…